Research programme: apoptosis stimulants - Ascenta

Drug Profile

Research programme: apoptosis stimulants - Ascenta

Alternative Names: SH-122; SM-122; SM-164; Smac-mediated cancer therapy - Ascenta

Latest Information Update: 14 Sep 2009

Price : $50

At a glance

  • Originator Ascenta Therapeutics
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Sep 2009 Preclinical development is ongoing in USA
  • 26 Mar 2009 Pharmacokinetics & pharmacodynamics data from preclinical trials in Cancer presented at the 237th American Chemical Society National Meeting (ACS-2009)
  • 24 Oct 2008 Preclinical pharmacodynamics data presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top